Literature DB >> 19853674

Epigenetic regulation of latent Epstein-Barr virus promoters.

Maria Takacs1, Ferenc Banati, Anita Koroknai, Judit Segesdi, Daniel Salamon, Hans Wolf, Hans Helmut Niller, Janos Minarovits.   

Abstract

Epigenotypes are modified cellular or viral genotypes that differ in transcriptional activity in spite of having an identical or nearly identical DNA sequence. Restricted expression of latent, episomal Epstein-Barr virus (EBV) genomes is a consequence of a series of epigenetic modifications. In tight latency, there is no virus production (lytic viral replication, associated with the expression of all viral genes), and only a limited set of viral promoters is activated in a host-cell-dependent manner. The latent EBV promoters control the expression of growth-transformation-associated viral genes. The role of major epigenetic mechanisms in the regulation of latent EBV promoters is variable. DNA methylation contributes to silencing of Wp and Cp (alternative promoters for transcripts coding for nuclear antigens EBNA 1-6) and LMP1p, LMP2Ap and LMP2Bp (promoters for transcripts encoding transmembrane proteins). DNA methylation does not control, however, Qp (a promoter for EBNA1 transcripts only) in B lymphoblastoid cell lines (LCLs, immortalized by EBV in vitro), although in vitro methylated Qp-reporter gene constructs are silenced. The invariably unmethylated Qp is probably switched off by binding of a repressor protein in LCLs. Histone modifications may also contribute to the regulation of latent EBV promoters because the active Cp, Qp and LMP2Ap promoters that are marked by strong binding of cellular regulatory proteins are located on "acetylation islands" enriched in diacetylated histone H3 and tetraacetylated histone H4. We speculate that binding of the chromatin insulator protein CTCF to 3 distinct sites (within, close to and far from the matrix attachment region) may contribute to the three-dimensional organization of the viral episomes. We also raise the point that latent EBV episomes may relocate to new nuclear subcompartments before the start of lytic EBV replication. We propose that a similar relocation of EBV episomes may result in a promoter switch (from Qp to Cp) due to the access of Cp to a B-lymphoblast-specific transcription factory when in vitro cultivated Burkitt's lymphoma cells undergo a phenotypic drift. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19853674     DOI: 10.1016/j.bbagrm.2009.10.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  32 in total

1.  The nucleotide polymorphisms within the Epstein-Barr virus C and Q promoters from nasopharyngeal carcinoma affect transcriptional activity in vitro.

Authors:  Feng-Wei Wang; Xian-Rui Wu; Wen-Ju Liu; Ying-Jie Liang; Yu-Fan Huang; Yi-Ji Liao; Chun-Kui Shao; Yong-Sheng Zong; Shi-Juan Mai; Dan Xie
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-12-07       Impact factor: 2.503

2.  Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation.

Authors:  E K Hoebe; C Wille; E S Hopmans; A R Robinson; J M Middeldorp; S C Kenney; A E Greijer
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

3.  Dissecting the mechanism of histone deacetylase inhibitors to enhance the activity of zinc finger nucleases delivered by integrase-defective lentiviral vectors.

Authors:  Alok V Joglekar; Libby Stein; Michelle Ho; Megan D Hoban; Roger P Hollis; Donald B Kohn
Journal:  Hum Gene Ther       Date:  2014-04-02       Impact factor: 5.695

4.  Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG's.

Authors:  Stefanie Weber; Barbara Weiser; Kimdar S Kemal; Harold Burger; Christina M Ramirez; Klaus Korn; Kathryn Anastos; Rupert Kaul; Colin Kovacs; Walter Doerfler
Journal:  Virology       Date:  2013-12-05       Impact factor: 3.616

5.  Epigenetic deregulation of the LMP1/LMP2 locus of Epstein-Barr virus by mutation of a single CTCF-cohesin binding site.

Authors:  Horng-Shen Chen; Kayla A Martin; Fang Lu; Lena N Lupey; Joshua M Mueller; Paul M Lieberman; Italo Tempera
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 6.  Epigenetic regulation of EBV persistence and oncogenesis.

Authors:  Italo Tempera; Paul M Lieberman
Journal:  Semin Cancer Biol       Date:  2014-01-24       Impact factor: 15.707

7.  Epstein-Barr virus-induced epigenetic alterations following transient infection.

Authors:  Krista J Queen; Mingxia Shi; Fangfang Zhang; Urska Cvek; Rona S Scott
Journal:  Int J Cancer       Date:  2012-11-02       Impact factor: 7.396

Review 8.  Keeping it quiet: chromatin control of gammaherpesvirus latency.

Authors:  Paul M Lieberman
Journal:  Nat Rev Microbiol       Date:  2013-11-06       Impact factor: 60.633

Review 9.  Occult hepatitis B virus and hepatocellular carcinoma.

Authors:  Teresa Pollicino; Carlo Saitta
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 10.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.